| Literature DB >> 33447460 |
Masahide Oki1, Hideo Saka1,2.
Abstract
Flexible bronchoscopes are being continuously improved, and an ultrathin bronchoscope with a working channel that allows the use of a radial-type endobronchial ultrasound (EBUS) probe is now available. The ultrathin bronchoscope has good maneuverability for passing through the small bronchi and good accessibility to peripheral lung lesions. This utility is particularly enhanced when it is used with other imaging devices, such as EBUS and navigation devices. Multimodality bronchoscopy using an ultrathin bronchoscope leads to enhanced diagnostic yield. 2020 Journal of Thoracic Disease. All rights reserved.Entities:
Keywords: Bronchoscopy; endobronchial ultrasound (EBUS); peripheral pulmonary lesions (PPLs); ultrathin bronchoscope; virtual bronchoscopic navigation (VBN)
Year: 2020 PMID: 33447460 PMCID: PMC7797850 DOI: 10.21037/jtd-2020-abpd-001
Source DB: PubMed Journal: J Thorac Dis ISSN: 2072-1439 Impact factor: 3.005
Figure 1Flexible bronchoscopes. (A) A 2.8-mm ultrathin bronchoscope with a 1.2-mm channel; (B) a 3.0-mm ultrathin bronchoscope with a 1.7-mm channel; (C) a 4.0-mm-diameter thin bronchoscope with a 2.0-mm-diameter channel; (D) a 4.8-mm standard bronchoscope with a 2.0-mm-diameter channel; and (E) a 5.9-mm therapeutic bronchoscope with a 3.0-mm-diameter channel.
Figure 2Fluoroscopic images showing the accessibility of a PPL using a 3.0-mm ultrathin bronchoscope and a 4.0-mm bronchoscope. (A) The EBUS probe could not be advanced towards the target lesion (arrow) using a 4.0-mm bronchoscope. (B) The 3.0-mm ultrathin bronchoscope approached the lesion and provided a diagnosis of adenocarcinoma. PPL, peripheral pulmonary lesion; EBUS, endobronchial ultrasound.
Studies on ultrathin bronchoscopy of PPLs
| Study | Year | Study design | Bronchoscope diameter (mm) | Guidance method | Mean lesion diameter (mm) | No. lesions | No. diagnosed | Yield (%) | No. lesions <2 cm | No. lesions <2 cm | Yield for lesions | Prevalence of malignancy (%) | Complications |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shinagawa ( | 2004 | Pro | 2.8 | CT, VBN | 13 | 26 | 17 | 65 | 26 | 17 | 65 | 69 | 0 |
| Yamamoto ( | 2004 | Pro | 2.8 | Flu | ND | 67 | 40 | 60 | ND | ND | ND | 76 | ND |
| Asano ( | 2006 | Pro | 2.8 | Flu, CT, VBN | 19 | 38 | 31 | 82 | 26 | 21 | 81 | 55 | ND |
| Shinagawa ( | 2007 | Pro | 2.8 | CT, VBN | 14 | 71 | 50 | 70 | 71 | 50 | 70 | 72 | 1 PTX |
| Tachihara ( | 2007 | Pro | 2.8 | Flu, VBN | 16 | 58 | 33 | 57 | 46 | 21 | 46 | ND | 0 |
| Oki ( | 2008 | Pro | 3.5 | Flu | 34 | 98 | 68 | 69 | 23 | 13 | 57 | 69 | 0 |
| Oki ( | 2009 | Pro | 3.4 | Flu, rEBUS | 31 | 71 | 49 | 69 | 14 | 5 | 36 | 62 | 0 |
| Eberhardt ( | 2010 | Pro | 2.8 | VBN | 28 | 25 | 20 | 80 | ND | ND | ND | 84 | 1 PTX |
| Matsuno ( | 2011 | Retro | 2.8 | Flu, CT | ND | 166 | 113 | 68 | ND | ND | ND | 58 | 1 PTX |
| Oki ( | 2012 | RCT | 3.4 | Flu, rEBUS | 26 | 101 | 66 | 65 | 25 | 10 | 40 | 75 | 3 PTX, 1 PNA, 1 bleeding |
| Asano ( | 2013 | RCT | 2.8 | Flu | 17 | 167 | 100 | 60 | 110 | 62 | 56 | 90 | 1 PTX, 1 lidocaine intoxication, 1 PNA |
| RCT | 2.8 | Flu, VBN | 18 | 167 | 112 | 67 | 114 | 74 | 65 | 86 | 1 PTX, 2 bleeding, 1 bradycardia | ||
| Oki ( | 2015 | RCT | 3.0 | Flu, rEBUS, VBN | 19 | 150 | 111 | 74 | 80 | 52 | 65 | 82 | 3 PTX, 1 PNA, 1 chest pain |
| Franzen ( | 2016 | RCT | 2.8 | Flu | 20 | 20 | 11 | 55 | 6 | ND | ND | 40 | 2 extensive coughing, 3 blocked working channel, 1 hypertension |
| Diez-Ferrer ( | 2019 | Pro | 2.8/3.1 | Flu, VBN | 23 | 55 | 26 | 47 | 26 | 11 | 42 | 60 | ND |
| Retro | 2.8/3.1 | Flu | 25 | 110 | 44 | 40 | 46 | 11 | 24 | 78 | ND | ||
| Ali ( | 2019 | Pro | 2.8 | Flu, VBN, CBCT | 20 | 40 | 36 | 90 | ND | ND | ND | 63 | 1 PTX, 1 lung abscess |
| Sehgal ( | 2019 | Retro | 3.0 | rEBUS | 16 | 34 | 19 | 56 | ND | ND | ND | ND | 1 PTX, 1 bleeding |
| Oki ( | 2019 | RCT | 3.0 | Flu, rEBUS, VBN | 19 | 177 | 124 | 70 | 102 | 64 | 63 | 80 | 2 PTX, 2 PNA, 1 bleeding |
| Sumi ( | 2020 | Retro | 3.0 | Flu, rEBUS | 20 | 102 | 77 | 75 | 65 | 46 | 71 | ND | 1 PTX, 2 PNA, 1 bleeding |
| Summary | 1,717 | 1,130 | 66% | 780 | 458 | 59% | 76% | Overall 3%, PTX 1% |
PPL, peripheral pulmonary lesion; CBCT, cone-beam computed tomography; Flu, fluoroscopy; ND, no data; PNA, pneumonia; Pro, prospective study; PTX, pneumothorax; RCT, randomized controlled trial; rEBUS, radial-probe endobronchial ultrasound; Retro, retrospective study, VBN, virtual bronchoscopic navigation.